TipRanks
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
US Market
MAZE
Maze Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see MAZE full AI Analyst Report?

Maze Therapeutics, Inc. (MAZE) Stock News & Sentiment

123 Followers
Maze Therapeutics Reiterated Buy as APOL1 Opportunity Expands; $64 Price Target Maintained
Premium
Ratings
Maze Therapeutics Reiterated Buy as APOL1 Opportunity Expands; $64 Price Target Maintained
21d ago
MAZE
Maze Therapeutics Strengthens Board with New Director Appointments
Premium
Company Announcements
Maze Therapeutics Strengthens Board with New Director Appointments
2M ago
8K
MAZE
Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization
Premium
Company Announcements
Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization
2M ago
MAZE
Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target
Premium
Ratings
Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target
2M ago
MAZE
Maze Therapeutics: Buy Rating Reiterated on Strong Cash Runway and Advancing APOL1/PKU Programs; Price Target Maintained at $57
Premium
Ratings
Maze Therapeutics: Buy Rating Reiterated on Strong Cash Runway and Advancing APOL1/PKU Programs; Price Target Maintained at $57
2M ago
MAZE
Maze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE Investors
Premium
Company Announcements
Maze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE Investors
3M ago
MAZE
Analyst Reaffirms Buy on Maze with Unchanged $110 Price Target, Citing Strong HORIZON Data and Favorable Risk-Reward
Premium
Ratings
Analyst Reaffirms Buy on Maze with Unchanged $110 Price Target, Citing Strong HORIZON Data and Favorable Risk-Reward
4M ago
MAZE
More MAZE News >

MAZE News on the Web

Analysts Are Bullish on Top Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Viking Therapeutics (VKTX)
TipRanks News
Bullish
Maze Therapeutics initiated with a Buy at Citi
TipRanks News
Bullish
Maze Therapeutics, Inc. at Citi Biopharma Back to School Summit Transcript
GuruFocus News
Neutral
Maze Therapeutics Execs Make Major Moves With Insider Stock Sales
TipRanks News
Neutral
Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization
TipRanks News
Bearish
Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN) and Maze Therapeutics, Inc. (MAZE)
TipRanks News
Bullish
Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target
TipRanks News
Bullish
Maze Therapeutics: Buy Rating Reiterated on Strong Cash Runway and Advancing APOL1/PKU Programs; Price Target Maintained at $57
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average3.25 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MAZE’s Media Buzz Sentiment?
Currently, no data Available
What is MAZE’s weekly average amount of articles?
In an average week, 3.25 articles about MAZE are published.
    What is MAZE’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    IQVIQVIA Holdings
    GILDGilead Sciences
    ABBVAbbVie
    VRTXVertex Pharmaceuticals
    NVSNovartis
    Showing the stocks with the most bullish news sentiment over the past week